Official Title
A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19
Brief Summary

A randomized, double-blind, placebo-controlled international multicenter clinical trial design will be adopted. A total of 29,000 subjects aged 18 years and above are planned to be recruited, including 750 subjects aged 18-59 years and 250 subjects aged 60 years and above in China; 21,000 subjects aged 18-59 years and 7,000 subjects aged 60 years and above will be recruited outside China. Safety and immunogenicity will be evaluated among the Chinese subjects, and efficacy, immunogenicity and safety will be evaluated among the subjects outside China. Among them, 750 subjects aged 18-59 and 250 subjects aged 60 and above from outside China and all subjects from China will be selected as the immunogenicity subgroup for immunogenicity bridging study. The IgG levels of SARS-COV-2 neutralizing antibody and RBD protein binding antibody will be detected by blood sampling before vaccination, 14 days and 6 months after full course of vaccination to evaluate the immunogenicity and immune persistence.

Detailed Description

After signing the informed consent form, the volunteers aged 18 years and above will receive
the relevant examinations after an inquiry by investigator of the medical history (including
COVID-19 history), recent medication(vaccine) history, allergy history and concomitant
medications, and demographic data collection by the investigators, including physical
examination (skin and mucous membranes, lymph nodes, head, neck, chest, abdomen,
spine/limbs), novel Coronavirus (SARS-COV-2) nucleic acid test and antibody test, urine
pregnancy (women of childbearing age) test, and vital signs (blood pressure, axillary/oral
temperature, pulse) evaluation.

Screening eligible subjects will be 1:1 randomly assigned to the experimental group and the
placebo control group, and vaccinated as per the 0, 1, 2 month immunization schedule.

All adverse events (AEs) up to 30 minutes after each dose of vaccination, all AEs from 0 to 7
days (including both solicited and unsolicited), and all AES from 8 to 30 days (unsolicited)
will be collected; All serious adverse events (SAEs) will be collected from the first dose of
vaccination to 12 months after the whole vaccination.

The incidence rate and efficacy of any severity of COVID-9 of any severity 14 days after
whole vaccination.

Blood samples (5ml) will be collected before the first dose of vaccination and 14 days and 6
months after the whole course of vaccination to detect neutralizing antibody of SARS-COV-2
and protein binding antibody IgG of receptor binding region (RBD) .

Active, not recruiting
Prevention of COVID-19
Safety and Efficacy

Biological: Recombinant new coronavirus vaccine (CHO cell) group

Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group

Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.

Eligibility Criteria

Inclusion Criteria:

- Population aged 18 years and above;

- Subjects voluntarily participate in the study and sign the informed consent form; and
are able to provide valid identification, and understand and comply with the
requirements of the trial protocol;

- Female subjects of childbearing age agree to use effective contraceptive measures from
the beginning of the study to 2 months after full course of vaccination.

Exclusion Criteria:

- Suspected or confirmed as fever(axillary temperature ≥37.3°C / oral temperature
≥37.5°C) within 72 hours before the enrollment, or axillary temperature ≥37.3°C / oral
temperature ≥37.5°C at the day of screening;

- Diastolic blood pressure ≥ 100mmhg and / or systolic blood pressure ≥ 150mmhg;

- Patients with previous history of a COVID-19;

- Detection of SARS-COV-2 nucleic acid or antibody is positive;

- Those who are suffering from the following diseases:

1. With thrombocytopenia, any coagulation dysfunction or receiving anti-coagulatory
treatment

2. Congenital or acquired immune deficiency or autoimmune disease history; no
spleen, or history of splenic surgery and trauma, or receiving immunomodulator
treatment within 6 months, e.g., immunosuppressive dose of glucocorticoids
(reference dose: equivalent to 20mg/ day of prednisone, over 1 week); Or
monoclonal antibodies; Or thymosin; Or interferon etc.; However, topical
application (such as ointment, eye drops, inhalers or nasal sprays) is permitted;

3. Symptoms related to acute respiratory tract infection (such as sneezing, nasal
congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of
breath, etc.);

4. Cancer patients (except basal cell carcinoma).

- With a history of serious allergy to any vaccine or any composition of Investigational
product (including: aluminum preparations), such as allergic shock, allergic throat
edema, allergic purpura, thrombocytopenic purpura, localized allergic necrosis
reaction (Arthus reaction), dyspnea and angioneuroedema;

- Inoculated with subunit vaccine and inactivated vaccine within 14 days before the
first dosing of investigational vaccine, or inoculated with attenuated live vaccine
within 30 days;

- Previous receiving blood transfusion or blood relevant products (including
immunoglobulin) within 3 months, or planning to receive such products from the
starting of study to <6 months after the whole-course inoculation;

- Have participated in or are participating in other covid-19 related clinical trials;

- Women in breastfeeding period or in pregnant period (including women at childbearing
age with positive result of urine pregnancy test);

- Considered by investigators as any disease or state possibly making the subject at
unacceptable risk; not conforming to the requirements of study protocol; interference
of assessment of reactions of vaccine.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Ecuador
Indonesia
Pakistan
Uzbekistan
Locations

Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China

Biodimed Guayaquil Clinical Research Center
Guayaquil, Guayas, Ecuador

Biodimed Alemania Clinical Research Center
Quito, Pichincha, Ecuador

Biodimed Eloy Alfaro Clinical Research Center
Quito, Pichincha, Ecuador

Fkui-Rscm
Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia

FK Unpad/RSHS
Bandung, Jawa Barat, Indonesia

Aziz Fatimah Hospital
Faisalabad, Punjab, Pakistan

Avicenna Hospital
Lahore, Punjab, Pakistan

Central Park Teaching Hospital
Lahore, Punjab, Pakistan

National Hospital & Medical Center
Lahore, Punjab, Pakistan

University of Health Sciences
Lahore, Punjab, Pakistan

Al-Shifa Trust Eye Hospital
Rawalpindi, Punjab, Pakistan

Indus Hospital and Health Network
Karachi, Sindh, Pakistan

Shaheed Zulfiqar Ali Bhutto Medical University
Islamabad, Pakistan

Family Hospital No.15
Tashkent, Uzbekistan

GUVD Poliklinika
Tashkent, Uzbekistan

IIV Markaziy Poliklinika
Tashkent, Uzbekistan

Toshkent viloyat IIV Poliklinika
Tashkent, Uzbekistan

Fangjun Li, Bachelor, Principal Investigator
Hunan Provincial Center for Disease Control and Prevention

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
NCT Number
MeSH Terms
COVID-19
Vaccines